• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

隐源性纤维性肺泡炎的预后

The prognosis of cryptogenic fibrosing alveolitis.

作者信息

Stack B H, Choo-Kang Y F, Heard B E

出版信息

Thorax. 1972 Sep;27(5):535-42. doi: 10.1136/thx.27.5.535.

DOI:10.1136/thx.27.5.535
PMID:4538877
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC470541/
Abstract

The course of cryptogenic fibrosing alveolitis (CFA) in 96 patients is described. The mean survival from the onset of the first symptom until death was 47·4 months in all the 59 fatal cases, 49·6 months in those dying from CFA only, and 48·4 months in those dying from CFA in whom the course of the illness was not influenced by corticosteroids. There was a wide variation in the natural course of the disorder, varying from death within a year of the onset of symptoms in five patients to prolonged survival with slow or arrested progress in four patients not treated with corticosteroids. Most patients died from CFA but five developed bronchial carcinoma and two died after lung biopsy. The main factor influencing the prognosis was the effectiveness of corticosteroid drugs. Only 16% of the treated patients had a worthwhile (grade 2) response to these drugs and the five-year survival of this group was 67%. In those patients in whom the course of the illness was uninfluenced by corticosteroids the five-year survival rate was only 20%. The histological appearances on lung biopsy gave a rough guide to the likely effect of corticosteroid therapy. Other factors influencing the prognosis were the degree of dyspnoea on presentation, the vital capacity, and the presence of arterial hypoxaemia. Patients who had had symptoms for more than four years before the first hospital attendance had a relatively good prognosis. By contrast, neither the extent of radiographic abnormality nor the presence of circulating rheumatoid and antinuclear factors influenced subsequent survival.

摘要

本文描述了96例隐源性纤维性肺泡炎(CFA)患者的病程。在59例死亡病例中,从首次出现症状到死亡的平均生存期为47.4个月,仅死于CFA的患者为49.6个月,疾病进程未受皮质类固醇影响、死于CFA的患者为48.4个月。该疾病的自然病程差异很大,5例患者在症状出现后1年内死亡,4例未接受皮质类固醇治疗的患者生存期延长,病情进展缓慢或停滞。大多数患者死于CFA,但5例发生支气管癌,2例在肺活检后死亡。影响预后的主要因素是皮质类固醇药物的疗效。仅16%的接受治疗的患者对这些药物有显著(2级)反应,该组患者的五年生存率为67%。在疾病进程未受皮质类固醇影响的患者中,五年生存率仅为20%。肺活检的组织学表现可为皮质类固醇治疗的可能效果提供大致指导。其他影响预后的因素包括就诊时的呼吸困难程度、肺活量和动脉血氧不足的存在。首次就诊前有症状超过4年的患者预后相对较好。相比之下,影像学异常的程度以及循环中类风湿因子和抗核因子的存在均不影响后续生存。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf32/470541/998195671d18/thorax00125-0028-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf32/470541/e96d24456ffc/thorax00125-0027-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf32/470541/998195671d18/thorax00125-0028-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf32/470541/e96d24456ffc/thorax00125-0027-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf32/470541/998195671d18/thorax00125-0028-a.jpg

相似文献

1
The prognosis of cryptogenic fibrosing alveolitis.隐源性纤维性肺泡炎的预后
Thorax. 1972 Sep;27(5):535-42. doi: 10.1136/thx.27.5.535.
2
The treatment of cryptogenic fibrosing alveolitis with immunosuppressant drugs.免疫抑制药物治疗隐源性纤维性肺泡炎
Q J Med. 1971 Apr;40(158):289-302. doi: 10.1093/oxfordjournals.qjmed.a067271.
3
Serial pulmonary function tests in fibrosing alveolitis.特发性肺纤维化的系列肺功能测试
Br J Dis Chest. 1972 Jan;66(1):33-44.
4
Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis.与系统性硬化症相关的纤维化肺泡炎比特发性纤维化肺泡炎预后更好。
Am J Respir Crit Care Med. 1994 Jun;149(6):1583-90. doi: 10.1164/ajrccm.149.6.8004317.
5
Cryptogenic fibrosing alveolitis: clinical features and their influence on survival.隐源性纤维性肺泡炎:临床特征及其对生存的影响。
Thorax. 1980 Mar;35(3):171-80. doi: 10.1136/thx.35.3.171.
6
Familial association of rheumatoid arthritis and fibrosing alveolitis.类风湿关节炎与肺纤维化的家族关联。
Ann Rheum Dis. 1974 May;33(3):191-5. doi: 10.1136/ard.33.3.191.
7
[Idiopathic fibrosing alveolitis in therapeutic practice].[治疗实践中的特发性肺纤维化]
Klin Med (Mosk). 2002;80(9):63-5.
8
The predictive value of appearances on thin-section computed tomography in fibrosing alveolitis.薄层计算机断层扫描表现对纤维化肺泡炎的预测价值。
Am Rev Respir Dis. 1993 Oct;148(4 Pt 1):1076-82. doi: 10.1164/ajrccm/148.4_Pt_1.1076.
9
Interstitial lung disease in dermatomyositis: clinicopathological study.皮肌炎中的间质性肺疾病:临床病理研究
J Rheumatol. 1987 Feb;14(1):102-7.
10
The significance of antinuclear and DNA antibodies in cryptogenic fibrosing alveolitis.抗核抗体和DNA抗体在隐源性纤维性肺泡炎中的意义。
Thorax. 1983 Jan;38(1):67-70. doi: 10.1136/thx.38.1.67.

引用本文的文献

1
Glucocorticoid therapy in respiratory illness: bench to bedside.糖皮质激素在呼吸系统疾病中的治疗:从基础到临床。
J Investig Med. 2022 Dec;70(8):1662-1680. doi: 10.1136/jim-2021-002161. Epub 2022 Jun 28.
2
Mortality and survival in idiopathic pulmonary fibrosis: a systematic review and meta-analysis.特发性肺纤维化的死亡率和生存率:一项系统评价与荟萃分析
ERJ Open Res. 2022 Mar 14;8(1). doi: 10.1183/23120541.00591-2021. eCollection 2022 Jan.
3
Rethinking Idiopathic Pulmonary Fibrosis.重新思考特发性肺纤维化。

本文引用的文献

1
Chronic diffuse interstitial fibrosis of the lungs.慢性弥漫性肺间质纤维化
Br Med J. 1960 Feb 13;1(5171):443-50. doi: 10.1136/bmj.1.5171.443.
2
DESQUAMATIVE INTERSTITIAL PNEUMONIA.脱屑性间质性肺炎
Am J Med. 1965 Sep;39:369-404. doi: 10.1016/0002-9343(65)90206-8.
3
IDIOPATHIC INTERSTITIAL FIBROSIS OF THE LUNGS. I. PROGNOSIS AS INDICATED BY RADIOLOGICAL FINDINGS.
Acta Med Scand. 1965 Jul;178:47-58.
Clin Chest Med. 2021 Jun;42(2):263-273. doi: 10.1016/j.ccm.2021.03.005.
4
Prognosis of idiopathic pulmonary fibrosis without anti-fibrotic therapy: a systematic review.特发性肺纤维化患者未接受抗纤维化治疗的预后:一项系统评价。
Eur Respir Rev. 2020 Aug 4;29(157). doi: 10.1183/16000617.0158-2019. Print 2020 Sep 30.
5
Characteristics of lung cancer among patients with idiopathic pulmonary fibrosis and interstitial lung disease - analysis of institutional and population data.特发性肺纤维化和间质性肺疾病患者的肺癌特征——机构和人群数据分析。
Respir Res. 2018 Oct 3;19(1):195. doi: 10.1186/s12931-018-0899-4.
6
Radiological characteristics, histological features and clinical outcomes of lung cancer patients with coexistent idiopathic pulmonary fibrosis.特发性肺纤维化合并肺癌患者的影像学特征、组织学特征和临床转归。
Lung. 2015 Feb;193(1):71-7. doi: 10.1007/s00408-014-9664-8. Epub 2014 Nov 9.
7
A novel telomerase activator suppresses lung damage in a murine model of idiopathic pulmonary fibrosis.一种新型端粒酶激活剂可抑制特发性肺纤维化小鼠模型中的肺损伤。
PLoS One. 2013;8(3):e58423. doi: 10.1371/journal.pone.0058423. Epub 2013 Mar 14.
8
Viruses as co-factors for the initiation or exacerbation of lung fibrosis.病毒作为肺纤维化起始或加重的辅助因素。
Fibrogenesis Tissue Repair. 2008 Oct 13;1(1):2. doi: 10.1186/1755-1536-1-2.
9
Idiopathic pulmonary fibrosis.特发性肺纤维化
Orphanet J Rare Dis. 2008 Mar 26;3:8. doi: 10.1186/1750-1172-3-8.
10
Acute exacerbations of idiopathic pulmonary fibrosis.特发性肺纤维化的急性加重
Am J Respir Crit Care Med. 2007 Oct 1;176(7):636-43. doi: 10.1164/rccm.200703-463PP. Epub 2007 Jun 21.
4
OPEN BIOPSY IN DIFFUSE PULMONARY DISEASE.
Am J Surg. 1964 Dec;108:867-9. doi: 10.1016/0002-9610(64)90049-2.
5
INTERSTITIAL PULMONARY FIBROSIS.间质性肺纤维化
J Thorac Cardiovasc Surg. 1964 Jun;47:799-808.
6
DIFFUSE INTERSTITIAL PULMONARY FIBROSIS.A CLINICAL, RADIOLOGICAL, AND PATHOLOGICAL STUDY BASED ON 45 PATIENTS.弥漫性间质性肺纤维化:基于45例患者的临床、放射学及病理学研究
Q J Med. 1964 Jan;33:71-103.
7
Pathophysiology of interstitial pulmonary fibrosis. Report of 19 cases and follow-up with corticosteroids.间质性肺纤维化的病理生理学。19例报告及糖皮质激素随访
Arch Intern Med. 1962 Nov;110:628-48. doi: 10.1001/archinte.1962.03620230074012.
8
Diffuse interstitial pulmonary fibrosis (Hamman-Rich syndrome) in an allergic patient: report of case.一名过敏患者的弥漫性间质性肺纤维化(哈曼-里奇综合征):病例报告。
Am J Med Sci. 1958 Jan;235(1):60-6. doi: 10.1097/00000441-195801000-00007.
9
Diffuse interstitial fibrosis of the lungs.肺部弥漫性间质纤维化
Am Rev Tuberc. 1953 Oct;68(4):603-14. doi: 10.1164/art.1953.68.4.603.
10
Diffuse fibrosing alveolitis (diffuse interstitial fibrosis of the lungs). Correlation of histology at biopsy with prognosis.弥漫性纤维化肺泡炎(肺弥漫性间质纤维化)。活检组织学与预后的相关性。
Thorax. 1967 Jul;22(4):291-304. doi: 10.1136/thx.22.4.291.